Here, we demonstrated that combining KRAS inhibitors with gemcitabine effectively overcomes the resistance phenotype associated with CDKN2A loss, highlighting a potential therapeutic strategy for this resistant subset of KRAS-mutant pancreatic cancer. This evidence concerns the gene CDKN2A and pancreatic neoplasm.